文献速递乳腺MRUS

高风险乳腺癌女性监测中临床乳腺检查与MRI效用比较

Comparison of the utility of clinical breast examination and MRI in the surveillance of women with a high risk of breast cancer.
PubMed 文献 · Clin Radiol · 2019-12-09

回顾性分析2016年圣詹姆斯医院385例高风险乳腺癌女性的监测性乳腺MRI与临床乳腺检查(CBE)。MRI召回率11.2%、活检率6.2%、癌症检出率1.6%(16/1000),CBE召回率6.2%、活检率0.2%、癌症检出率0%。作者认为MRI敏感性支持其监测价值,CBE未检出癌症,提示其非关键组成部分;英国指南7%召回率目标未达到。

要点

  • 高风险乳腺癌监测中,MRI癌症检出率为1.6%(16/1000),CBE为0%。
  • MRI召回率11.2%,CBE召回率6.2%;MRI活检率6.2%,CBE为0.2%。
  • 英国指南推荐的7%召回率目标在本研究及文献其他研究中均未达到。

核心结论

  • 本研究高癌症检出率支持乳腺MRI监测具有无可比拟的敏感性。
  • 本研究未通过CBE检出任何乳腺癌,提示CBE不是高风险女性监测方案的关键组成部分。
  • 当前英国指南推荐的7%召回率目标在本研究及文献其他研究中均未达到,共同提示该指南可能未反映临床实践中可达到的水平。

研究设计与样本

  • 回顾性研究,收集2016年圣詹姆斯医院所有高风险乳腺癌女性的监测性MRI检查数据,共385例乳腺监测MRI检查和CBE。
  • 收集数据包括年龄、MRI指征、MRI评分、超声指征和评分及组织学结果;超声评分记录自CBE评分≥3分的病例。

诊断标准与关键数值

  • 乳腺MRI召回率为11.2%,CBE召回率为6.2%。
  • MRI活检率为6.2%,CBE活检率为0.2%。
  • MRI筛查癌症检出率为1.6%(即每1000例中16例),CBE癌症检出率为0%。

临床应用与阅片要点

  • 作者认为乳腺MRI监测具有无可比拟的敏感性,CBE未检出癌症,提示其不是高风险女性监测方案的关键组成部分。
  • 英国指南推荐的目标召回率为7%,本研究未达到,作者认为该指南可能未反映临床实践中可达到的水平。

局限性

  • 本研究未达到英国指南推荐的7%召回率目标,且文献中其他研究亦未达到,提示指南目标可能不反映临床实践可达水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To review surveillance magnetic resonance imaging (MRI) and clinical breast examinations (CBE) performed for women at high risk of breast cancer in order to determine recall and cancer-detection rates.

MATERIALS AND METHODS: Data were collected on all surveillance MRI examinations performed at St James's Hospital in 2016 for women at high risk of developing breast cancer. Data collected included age, indication for MRI, MRI score, ultrasound indications and scores, and histology findings. Ultrasound scores were recorded from CBEs that received a score of ≥3.

RESULTS: A total of 385 breast surveillance MRI examinations and CBEs were performed for women at high risk of breast cancer. A recall rate of 11.2% was documented for breast MRI examinations, whereas a recall rate of 6.2% was identified for CBEs. The biopsy rate was 6.2% for MRI and 0.2% for CBE. The cancer detection rate was 1.6% or 16 per 1,000 for MRI screening and 0% for CBE.

CONCLUSION: The high cancer detection rate in the present study supports the unparalleled sensitivity of breast MRI surveillance. Furthermore, the present study did not identify any breast cancers through CBE, suggesting it is not a critical component of the surveillance programme of high-risk women. The current UK guidelines recommending a target recall rate of 7% were not met in the present study or by other studies in the literature, collectively suggesting the guidelines may not be reflective of what is attainable in clinical practice.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Mihalco SP, Keeling SB, Murphy SF, et al. Comparison of the utility of clinical breast examination and MRI in the surveillance of women with a high risk of breast cancer. Clin Radiol. 2019. PMID: 31822366. doi:10.1016/j.crad.2019.09.145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。